Blog
About

12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Analysis of the methylation status of HPV DNA in human cell lines

      1, 2, 3, 1,3

      BMC Cancer

      BioMed Central

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background DNA methylation is an important epigenetic process that regulates gene expression mainly through its effect on chromatin conformation. It involves the stable maintenance of methylated cytosines at CpG dinucleotides (meCpGs) which in turn can regulate gene expression by two mechanisms: by direct interference with transcription factors binding to their target sequences, or by binding MeCP2 proteins, which recognize methylated DNA and recruit histone deacetilases, resulting in a highly compact chromatin structure. Human Papillomavirus (HPV) E2 protein controls various viral processes, including gene transcription and DNA replication. These activities rely upon its ability to bind as an homodimer to its target sequences (5'-ACCGN4CGGT-3') in the viral DNA. Since these sequences contain CpG dinucleotides, they are potential targets for DNA methylation, and, in fact, it has been demonstrated that E2's ability to bind to its cognate sequence is inhibited by methylation. Different studies have shown that the methylation patterns of HPV DNA, in the long control region (LCR) and the 3' region of the L1 gene, are heterogeneous in human cell lines and clinical samples. The objective of this study was to determine the methylation status of HPV type 18 and 16 DNA in different human-derived cell lines. Materials and methods DNA from HeLa, ViPa and CaLo cell lines (with integrated HPV type 18 DNA) was extracted and modified with sodium bisulfite. The 5' region of the L1 gene, the complete LCR (divided in three regions) and the 5' region of the E6 gene, were amplified using specific primers designed for modified DNA. These PCR fragments were cloned in TOPO A vector and 10 clones from each cell line were sequenced for analysis. Results DNA methylation patterns observed in three different cell lines containing HPV type 18 DNA showed great similarity. No methylation of CpG dinucleotides was observed in the complete LCR and the 5' region of the E6 gene in CaLo cell line. Similarly, the enhancer and promoter regions within the LCR, and the 5' region of E6 were unmethylated in HeLa and ViPa cell lines. However, the 5' region of the L1 gene, although mostly hypermethylated in HeLa and CaLo, exhibited an heterogeneous pattern in ViPa cells. Interestingly, the CpG at position 7318 (within the 5' region of the LCR) was consistently found methylated in two cell lines (HeLa and ViPa), as opposed to CaLo where it was found unmethylated. Conclusion The methylation patterns of HPV 18 DNA in these three cell lines are very similar, with the LCR generally unmethylated. The heterogeneity of the methylation patterns in the 5' region of the L1 gene reported in previous studies was confirmed in the present work. Further studies are needed in order to determine if these patterns are consistent in tumor samples, and how they correlate with various stages of the carcinogenic process and the viral life cycle. Further analysis using methylation-specificand Headloop suppression PCR will be useful to establish the CpG methylation patterns of the viral genome in different types of lesions (low and high grade) and during different stages of the viral life cycle.

          Related collections

          Author and article information

          Affiliations
          [1]Division of Basic Research, Instituto Nacional de Cancerología, Mexico City, Mexico
          [2]Facultad de Química, UNAM, Mexico City, Mexico
          [3]Department of Molecular Biology and Biotechnology, Instituto de Investigaciones Biomédicas, UNAM, Mexico City, Mexico
          Contributors
          Conference
          BMC Cancer
          BMC Cancer
          BioMed Central (London)
          1471-2407
          2007
          5 February 2007
          : 7
          : Suppl 1
          : A26
          1796570
          1471-2407-7-S1-A26
          10.1186/1471-2407-7-S1-A26
          Copyright © 2007 Méndez et al; licensee BioMed Central Ltd.
          24th Annual Meeting of the National Cancer Institute of Mexico
          Mexico City, Mexico
          14–17 February 2007
          Categories
          Meeting Abstract

          Oncology & Radiotherapy

          Comments

          Comment on this article